Repligen Corporation
RGEN
Classifica tra le azioni
#1888
Repligen Corporation specializes in the creation and distribution of advanced... Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Prezzo delle azioni
$179.82
Capitalizzazione di mercato
$11.42B
Variazione (1 giorno)
1.92%
Variazione (1 anno)
16.36%
Paese
US
Scambia Repligen Corporation (RGEN)
Categoria
Healthcare
Utile per Repligen Corporation (RGEN)
Utile nel Jun 2026 TTM: $52.15M
Secondo gli ultimi rapporti finanziari di Repligen Corporation, gli utili attuali della società sono $52.15M. Nel 2023, la società ha registrato un utile di $56.71M, una diminuzione rispetto a agli utili del 2022, che erano di $219.14M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Repligen Corporation dal 2000 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $52.15M | -292.90% |
| 2024 | $-27.04M | -147.67% |
| 2023 | $56.71M | -74.12% |
| 2022 | $219.14M | 42.72% |
| 2021 | $153.54M | 159.29% |
| 2020 | $59.22M | 126.44% |
| 2019 | $26.15M | 22.00% |
| 2018 | $21.44M | 195.75% |
| 2017 | $7.25M | -38.01% |
| 2016 | $11.69M | -12.90% |
| 2015 | $13.42M | 20.51% |
| 2014 | $11.14M | -51.60% |
| 2013 | $23.01M | 104.18% |
| 2012 | $11.27M | -26,005.92% |
| 2011 | $-43.51K | -99.11% |
| 2010 | $-4.90M | -184.86% |
| 2009 | $5.77M | -84.78% |
| 2008 | $37.93M | -4,365.78% |
| 2007 | $-889.26K | -227.61% |
| 2006 | $696.86K | -123.36% |
| 2005 | $-2.98M | -68.76% |
| 2004 | $-9.55M | 110.51% |
| 2003 | $-4.54M | 1.71% |
| 2002 | $-4.46M | -15.50% |
| 2001 | $-5.28M | 38.32% |
| 2000 | $-3.82M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $3.81B | 7,197.79% |
US
|
|
| $4.11B | 7,778.89% |
FR
|
|
| - | - |
JP
|
|
| $1.59B | 2,948.90% |
US
|
|
| - | - |
CH
|
